BCTX (Briacell Therapeutics Corp. Common Shares) Stock Analysis - Analyst Ratings

Briacell Therapeutics Corp. Common Shares (BCTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCTX trades at $3.98 with a market cap of $24.29M and a P/E ratio of -0.06. BCTX moved +9.69% today. Year to date, BCTX is -49.28%; over the trailing twelve months it is -89.10%. Its 52-week range spans $2.98 to $214.50. Rallies surfaces BCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate BCTX?

The average price target is $0.00.

BCTX Key Metrics

Key financial metrics for BCTX
MetricValue
Price$3.98
Market Cap$24.29M
P/E Ratio-0.06
EPS$-62.19
Dividend Yield0.00%
52-Week High$214.50
52-Week Low$2.98
Volume1.20K
Avg Volume0
Revenue (TTM)$0
Net Income$-26.56M
Gross Margin0.00%

BCTX Analyst Consensus

BCTX analyst coverage data. Average price target: $0.00.

Latest BCTX News

Recent BCTX Insider Trades

  • Lustig Marc bought 902.93K (~$2.00M) on May 14, 2024.
  • Bondarenko Jamieson bought 28.00K (~$128.24K) on Dec 28, 2022.
  • Bondarenko Jamieson bought 22.00K (~$117.70K) on Dec 20, 2022.

Common questions about BCTX

What do analysts rate BCTX?
The average price target is $0.00.
Does Rallies show BCTX price targets?
Yes. Rallies tracks BCTX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is BCTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BCTX. It does not provide personalized investment advice.
BCTX

BCTX